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A properly validated scoring system allowing objective categorization of infants with acute
respiratory infections (ARIs), avoiding the need for in-person assessment and that could
also be used by non-health professionals is currently not available. We aimed to develop a
new clinical assessment scale meeting these specifications.
Methods
We designed a clinical scale (ReSVinet scale) based on seven parameters (feeding intoler-
ance, medical intervention, respiratory difficulty, respiratory frequency, apnoea, general
condition, fever) that were assigned different values (from 0 to 3) for a total of 20 points.170
children under two years of age with ARI were assessed independently by three pediatri-
cians using this scale. Parents also evaluated their offspring with an adapted version of the
scale in a subset of 61 cases. The scale was tested for internal consistency (Cronbach’s
alpha), Pearson correlation coefficient for the items in the scale, inter-observer reliability
(kappa index) and floor-ceiling effect.
Results
Internal consistency was good for all the observers, with the lowest Cronbach’s alpha being
0.72. There was a strong correlation between the investigators (r-value ranged 0.76–0.83)
and also between the results obtained by the parents and the investigators(r = 0.73). Light’s
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kappa for the observations of the three investigators was 0.74. Weighted kappa in the group
evaluated by the parents was 0.73. The final score was correlated with length of hospital
stay, PICU admission and Wood-Downes Score.
Conclusions
The ReSVinet scale may be useful and reliable in the evaluation of infants with ARI, particu-
larly acute bronchiolitis, even with data obtained from medical records and when employed
by parents. Although further studies are necessary, ReSVinet scale already complies with
more score validation criteria than the vast majority of the alternatives currently available
and used in the clinical practice.
Background and Aims
Acute Respiratory Infections (ARI), and more specifically bronchiolitis, constitute a major
cause of morbidity and mortality in infants throughout the world [1,2,3]. Even though the clin-
ical characteristics, pathophysiology and course of ARI in infancy are well known, there is no
consensus with regards to how best to measure the severity of disease and the impact of thera-
peutic or preventive interventions in clinical trials [4, 5].
Many clinical scores have been published and even validated for the evaluation of infants
with ARI and/or bronchiolitis, although none of them has been sufficiently validated to allow
meaningful use in children [5]. These scales incorporate a variety of end points, and they all
have important limitations. These include the following: they are designed for medical person-
nel, they rely on in-person assessment of the patient by a physician (neglecting clinical records
and parental opinion), many of them are focused only in the respiratory status of the patient,
and in most cases they require parameters that are not universally available (such as oxygen
saturation or invasive procedures) [6,7].
No score has been validated as a research tool in the setting of pediatric respiratory infec-
tions; many of them are focused only in the respiratory status of the patient, and most, if not
all, require in-person evaluation, which may be particularly difficult to ensure in outpatient
clinical trials [5, 7]. We also currently lack a scale that could be used by parents and physicians
alike. Clinicians in emergency departments and primary settings, as well as professionals
involved in outpatient clinical trials, could all benefit greatly from such a scoring system. Doc-
tors could have a reliable tool, allowing parents to monitor the evolution of children at home,
establishing objective thresholds for patient referral or to seek of medical assistance. In addi-
tion, in the setting of clinical trials, having a validated score that parents can use would allow
objective follow-up after hospital discharge or in case of mild diseases.
The goal of this project was to develop and evaluate a global clinical severity scale (ReSVinet
scale) that would be amenable to be used in outpatient and inpatient studies without the need
of in-person assessment. Internal reliability, construct validity, and ease of applicability of the
scale were assessed. Additionally, the validity and reproducibility of an adapted version of this
score in non-medical language for parental use was evaluated.
Methods
All necessary ethical permissions were obtained from the regional ethics committee in Galicia
(Spain) prior to the beginning of this study, which was approved by the aforementioned
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Institution on 23 March 2010 (registration number 2010/015). Written informed consent was
obtained from all participants’ legal guardians before each patient was included in the study.
a- Score design
The main investigators, with substantial research experience in pediatric respiratory infections,
systematically reviewed studies that reported on the use of a respiratory score in children with
ARI. The following symptoms and clinical findings were initially considered as indicative of
disease severity: general condition, respiratory difficulty, oxygen saturation by pulse oxymeter,
cyanosis, apnea, food tolerance, tachypnea, and tachycardia. Finally some of these symptoms
were either included as part of a single component of the score, or excluded for being consid-
ered redundant or for limiting the applicability of the score in non-hospital settings and/or by
non-medical personnel.
The proposed score was submitted for evaluation to 90 pediatricians of outpatient, hospital
care and pediatric critical setting from the Galician Pediatric Research Network (REGALIP)
and from the FIVE research group [8]. They agreed on the ease of recording and value of the
parameters included. The final ReSVinet scale is detailed in Table 1, consisting of seven differ-
ent items with different value ranges assigned, which add up to a total score that spans from 0
to 20.
We aimed to validate this scale using information obtained from patients’medical records.
Our secondary aim was to provide the parents with a simple tool for evaluating the severity of
their children’s disease. The scale was thus developed to cover an important limitation of the
scoring systems currently available: none of them was designed for use by non-medical person-
nel. All the components as explained in the scale should be easily evaluated by a parent/care-
giver with no previous training. This resulted in an adapted version of the ReSVinet scale
written in plain Spanish language (Table 2).
b- Study Population
Patients were prospectively recruited among those admitted during two consecutive seasons in
three hospitals in Spain. Although the ReSVinet scale was initially conceived as a tool for the
entire pediatric age scope, a homogeneous group was defined in order to minimize biases: only
previously healthy children under two years of age with the diagnosis upon admission of acute
respiratory infection were included in the study. Infants with relevant underlying diseases
(including cardiac disease, chronic pulmonary problems, anatomic malformations, neurologic
diseases, severe malnutrition, immunodeficiency or hematologic malignancies) were excluded.
The parents of those fulfilling the above criteria were asked to participate in the study right
after their children had been admitted and, if informed consent was given, infants were allo-
cated to one of the following two cohorts:
• In group 1 (professional; G1), the clinical records of 170 children were retrospectively evalu-
ated using the new scale by three physicians (Observer 1-O1-, Observer 2 –O2-, Observer 3
–O3-) with expertise in the emergency setting.
• In group 2 (parental; G2), the clinical status of 61 patients was assessed by their caregivers at
the moment of discharge using an adapted version of the scale. Their results were compared
to those obtained by a physician blinded to the parental score (O1) who reviewed the medical
history of patients from G2 upon discharge. When parents consented to take part in the
study, simple directions on how to complete the scale were offered by a study nurse, who out-
lined the different items reading them to the parents to make sure that they were perfectly
understood, and offered them the possibility of asking their doubts about the study. Parents
The ReSVinet Scale
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should answer those questions using their own conception about severity in each item. They
had no access to medical records. Respiratory rate references were avoided in the parental
version as their inclusion could require standardized training. Whenever possible, infants
were always fed by parents. Children were clinically assessed on a daily basis by a doctor not
involved in the evaluation of the score. The same doctor then offered the legal tutors infor-
mation on the evolution of the illness, treatment options and test to be performed as a part of
Table 1. ReSVinet scale. This table presents the original scale, and was the one used by the three investigators.
Item 0 points 1 points 2 points 3 points
1 Feeding
intolerance
No Mild Decreased appetite and/or
isolated vomits with cough.
Partial Frequent vomits with
cough, rejected feed but able to
tolerate fluids sufficiently to ensure
hydration.
Total Oral intolerance or
absolute rejection of oral feed,






No Basic Nasal secretions aspiration,





were needed (chest X-rays, blood




support with positive pressure
(either non-invasive in CPAP,





No Mild Not in basal situation but
does not appear severe.
Wheezing only audible with
stethoscope, good air entrance. If
modified Wood Downes, Wang
score or any other respiratory
distress score is applied, it
indicates mild severity.
Moderate Makes some extra
respiratory effort (intercostal and/or
tracheosternal retraction).
Presented expiratory wheezing
audible even without stethoscope,
and air entrance may be
decreased in localized areas. If
modified Wood Downes, Wang
score or any other respiratory
distress score is applied, it
indicates moderate severity.
Severe Respiratory effort is
obvious. Inspiratory and
expiratory wheezing and/or
clearly decreased air entry. If
modified Wood Downes, Wang
score or any other respiratory




Normal < 2 m: 40–50





Mild or occasional tachypnea
Presented episodes of tachypnea,
well tolerated, limited in time by




tachypnea Tachypnea persisted or
recurred despite secretion
aspiration and/or nebulization with
bronchodilators.
Severe alteration Severe and
sustained tachypnea. Very
superficial and quick breath rate.
Normal/low breath rate with
obvious increased respiratory
effort and/or mental status
affected. Orientative rates of
severe tachypnea: < 2 m: > 70
bpm 2–6 m: > 60 bpm 6-12m:
>55 bpm 12-24m: >50 bpm 24-
36m: >40 bpm






Normal Mild Not in basal situation, child
was mildly uncomfortable but does
not appear to be in a severe
condition, not impress of severity.
Parents are not alarmed. Could
wait in the waiting room or even
stay at home.
Moderate Patient looks ill, and will
need medical exam and eventually
further complementary exams and/
or therapy. Parents are concerned.
Cannot wait in the waiting room.
Severe Agitated, apathetic,
lethargic. No need of medical
training to realize severity.
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routine care. Routine care was the same for all infants, whether they were taking part in the
study or not. Physicians in charge of scoring the severity of the illness did not take part in the
everyday clinical care of those children, and made no decisions on the tests a patient should
undergo or on treatment changes. At the moment of discharge, the caregivers completed
their version of the ReSVinet scale as if the child was in his or her worst moment during
admission.
In both sets of patients, clinical information and demographic data were registered in stan-
dardized forms by either investigators or parents. A descriptive analysis of the recorded vari-
ables was performed.
c- Score assessment
Our scale was tested in terms of internal reliability, construct validity, and ease of applicability:
Table 2. Adapted version of the ReSVinet scale for parental use.
Item 0
points
1 points 2 points 3 points
1 Feeding
intolerance
No Mild Decreased appetite (the child did
not eat the same as normally) and/or
presented isolated vomits with or without
cough.
Partial Frequent vomits with cough, but
the child does not vomit with every intake.
Feeding exhausts the child.
Total Child is unable to feed him/
herself. The use of a nasogastric




No Basic The child’s respiratory secretions
required removal, he or she was
explored by a physician or received
sporadically nebulized medication.
Antipyretics were administered.
IntermediateThe child required oxygen
therapy, underwent a chest X-ray
exploration, or a blood sample was
extracted. Treatment with nebulized
drugs was given regularly.
High The child required
respiratory support with a
machine. Respiratory support
was given through a special mask
applied on the nose or mouth or
resting on the child’s face, or
through an endotracheal tube.
3 Respiratory
difficulty
No Mild The child was not breathing
normally, but he/she does not seem to
have any difficulty when drawing air.
Moderate The child made an effort for
breathing. Respiratory noises can be
heard without the need of a stethoscope
(just approaching the ear to his or her
chest).
Severe Respiratory effort was
obvious. The child made
important movement of his/her
chest, the chest even collapses
with every movement, and
muscles of neck and belly were
used. A lot of respiratory noise
was heard without approaching
the ear to the child’s chest.
4 Respiratory
frequency
Normal Mild or occasional tachypnea The child
breathed more rapidly, but the situation
was well tolerated, or the respiratory
frequency was normalized after removing
secretions from respiratory airways or
administering nebulized medication.
Prolonged or recurrent tachypnea The
child breathed more rapidly in a more
persistent manner, even after receiving
nebulized medication or removing
secretions from respiratory tract.
Severe alteration The child
breathed quickly and superficially,
or really deeply. The child was
agitated or drowsy. Orientative
rates of severe tachypnea:
5 Apnea No Yes The child stopped breathing.
It may have been necessary to
stimulate him/her in order to
regain normal breathing rate.
6 General
Condition
Normal Mild Child did not seem the same as
always, but there did not seem to be
anything to worry about.
Moderate Child looked ill, and medical
examination was required, but it did not
feel like a life-threatening situation.
Severe Child was agitated,
apathetic,and/or lethargic. He/she
required urgent medical attention.
There was no need to be a doctor
to see that the clinical situation of
the child is worrying.
7 Fever No Yes, mild Rectal or tympanic
temperature < 38.5°C, or axillar
temperature < 38°C
Yes, moderate Rectal or tympanic
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c.1.) Validity. Construct validity was assessed by examining the correlation between the
score and other measures of impact of the disease: modified Wood-Downes Score [WDS] (as
the most widely used score in our setting) [9], length of stay, PICU internment, treatments
received and duration of admission. Optimal cut-points methods were used to establish a
severity threshold for the total score [10]. Pearson’s and Spearman’s Rho correlation coeffi-
cients were used to analyze correlation with quantitative variables. In order to compare the dis-
tribution of the score among groups of patients, Wilcoxon test and Kruskal-Wallis test were
employed.
c.2) Reliability. Inter-observer reliability was assessed for the total score using a weighed
kappa for each paired couple of investigators in G1, and for O1 and parents in the second
cohort. For the first subset of patients, we also obtained the Light’s kappa for more than two
observers (i.e, the mean of the kappa values obtained comparing each pair of investigators).
Intra-class correlation coefficients were also used to assess inter-observer reliability. Internal
consistency was evaluated using Cronbach’s alpha for each of the observers (O1, O2, and O3)
and for the parental cohort. Scales with Cronbach’s alpha values>0.7 are considered to have
good internal consistency [5, 11,12,13].
c.3) Utility. Individual items were reviewed for missing data and floor and/or ceiling
effects. Percentages of missing data of less than 10% and floor/ceiling effects<15% are gener-
ally considered acceptable.
All statistical calculations were carried out using the packages stats, psy andmultilevel from
R Software, version 3.1.1. (https://www.r-project.org). Level of significance was set to P-
value< 0.05.
Results
The three investigators completed all of the scales, whereas 60 of the 61 parents who agreed to
do so completed all the items of the score (one of the patients was discharged without having
his parents filled in their version of the score). Demographics and clinical aspects of “profes-
sional” and “parental” cohorts are summarized in Tables 3 and 4, respectively. Median age
(interquartilic range) was 6.5 (2.0–9.5) months for the “professional” cohort while it was 2.3
(1.8–6.3) months for the “parental” cohort. Score results for each subject can be seen in Fig 1.
Cronbach’s alpha for the results obtained by each of the observers and for parental subgroup
was greater than 0.70 in all cases (r-value ranged from 0.72 to 0.79) for the professional cohort
(G1), 0.73 for the parental cohort (G2).
Weighed kappa values for each paired couple of investigators was 0.77 for O1-O2, 0.71 for
O1-O3 and 0.74 for O2-O3 in the first cohort. Light’s kappa for more than two observers was
0.74. The weighed kappa for the group evaluated by parents and O1 was 0.73. There was a
strong correlation between the results obtained by investigators (r-value ranged from 0.76 to
0.83) and also between the results obtained by the parents and the investigators (r = 0.73).
O1 allocated 2.4% of the patients evaluated to the extreme endpoints of the scale (Total
score 0 or 20). Rates for O2 and O3 were 0.59% and 0.0%, respectively. Only 1.7% of children
reviewed by their parents were given an extreme value.
Changes in the score depending on several clinical conditions were sought. Only those
patients who were admitted to a Paediatric Intensive Care Unit (p<0.001 for both cohorts) or
those receiving Heliox (a fixed mixture of 30% oxygen and 70% helium) (P-value< 0.001 for
G1 and P-value = 0.002 for G2) were found to have a statistically significant higher score in
both cohorts. A previous episode of wheezing could be related to a more severe disease in the
sample assessed by professionals (P-value = 0.012) but not in the parental cohort (P-
value = 0.672). RSV was identified as the agent causing the disease in 77.1% (G1) and 81% (G2)
The ReSVinet Scale
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Table 3. Results of the ReSVinet scale in the professional cohort (Group 1). This table categorizes patients according to clinical, epidemiological and
outcome variables in the cohort evaluated by three pediatricians.
Observer 1 Observer 2 Observer 3 Least significant association
Descriptive análisis1 Mean (SD)2 Mean (SD)2 Mean (SD)2 P-value3
ReSVinet Score 11.4 (3.4) 10.6 (3.5) 10.4 (3.1)
Sex 0.101 (O3)
Male 63.5% (108/170) 12.0 (3.4) 11 (3.6) 10.7 (3.1)
Female 36.5% (62/170) 10.5 (3.1) 9.8 (3.2) 9.8 (3.1)
Age 0.790 (O2)
< 1 year 85.3% (145/170) 10.9 (4.0) 10.3 (3.8) 10 (3.5)
1–2 years 14.7% (25/170) 11.5 (3.3) 10.6 (3.5) 10.5 (3.1)
Previous wheezing episode 0.012 (O3)
Yes 37.1% (62/167) 12.9 (3.5) 11.9 (3.9) 11.3 (3.6)
No 62.9% (105/167) 10.6 (3) 9.7 (3.1) 9.9 (2.7)
Prematurity 0.928 (O3)
Yes 8.4% (14/167) 12.6 (4.3) 10.7 (4.8) 10.7 (3.7)
No 91.6% (153/167) 11.3 (3.3) 10.5 (3.4) 10.4 (3.1)
Nebulized epinephrine 0.120 (O3)
Yes 57.6% (98/170) 12 (3.5) 11.1 (3.6) 10.7 (3.7)
No 42.4% (72/170) 10.7 (3.2) 9.8 (3.2) 10.4 (3.1)
Antibiotics < 0.001
Yes 58.8% (100/170) 12.4 (3.5) 11.5 (3.4) 11.3 (2.9)
No 41.2% (70/170) 10.1 (2.6) 9.1 (3.2) 9.1 (3)
Heliox < 0.001
Yes 37.3% (63/169) 14.1 (3.2) 13.3 (3.3) 12.4 (2.9)
No 62.7% (106/169) 9.9 (2.4) 8.9 (2.5) 9.2 (2.6)
Suspected bacterian (super)infection 0.001 (O2-O3)
Yes 41% (68/166) 12.6 (3) 11.6 (3.2) 11.5 (2.7)
No 59% (98/166) 10.7 (3.4) 9.9 (3.6) 9.7 (3.2)
RSV detected4 0.739 (O2)
Yes 77.1% (128/166) 11.4 (3.4) 10.6 (3.5) 10.7 (3)
No 22.9% (38/166) 11.7 (3.3) 10.6 (3.6) 9.8 (3.6)
PICU admission < 0.001
Yes 21.8% (37/170) 15.7 (2.6) 15.4 (2.7) 14 (2.6)
No 78.2% (133/170) 10.2 (2.5) 9.2 (2.4) 9.4 (2.4)
Wood-Downes Score <0.001
< = 3 27.6% (42/152) 9.6 (2.9) 8.2 (2.5) 8.6 (2.8)
4–6 50% (76/152) 11.1 (2.7) 10.2 (2.7) 10.2 (2.5)
7 22.4% (34/152) 15.1 (3.1) 14.7 (3.0) 13.7 (2.9)
Hospital Length of Stay5 7.9 (3.9) 0.49 0.48 0.60 <0.001
1 Descriptive analysis: Data are expressed either as % (n/total of patients for which this condition was recorded in medical history) or as mean (SD).
2 Mean (standard deviation) of ReSVinet scale according to each rater and the different variables. Correlation was assessed by Wilcoxon’s test for
dichotomic variables, Kruskal-Wallis for discrete variables with more than two categories and Spearman’s correlation for continuous variables.
3 The p-value on the table represents the least significant one among all the observers (the case presenting the least significant value is indicated
between brackets).
4 The method used for detecting RSV (Respiratory Syncytial Virus) in respiratory secretions of our patients was direct immunofluorescence.
5 Spearman’s correlation coefficient was used for the statistical analysis. Mean length of stay expressed as days (SD).
doi:10.1371/journal.pone.0157665.t003
The ReSVinet Scale
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Table 4. Results of the ReSVinet scale in the parental cohort (group 2). This table reflects the results of the score obtained by a physician (observer 1)
and parents and the relation of the values obtained with clinical, epidemiological and outcome variables.
Observer 1 Parent Less significant association
Descriptive análisis1 Mean (SD)2 Mean (SD)2 P-value3
ReSVinet Score 11.7 (3.3) 11.2 (3.3)
Sex 0.968 (P)
Male 68.3% (41/60) 12 (3.5) 11.3 (3.4)
Female 31.7% (19/60) 10.8 (2.8) 11 (3.1)
Age 0.880 (O1)
< 1 year 88.3% (53/60) 11.3 (3.4) 12.1 (4)
1–2 years 11.7% (7/60) 11.7 (3.3) 11.1 (3.2)
Previous wheezing episode 0.672 (P)
Yes 35.6% (21/59) 11.3 (2.5) 11.1 (3.1)
No 64.4% (38/59) 11.9 (3.7) 11.3 (3.4)
Prematurity 0.135 (O1)
Yes 8.5% (5/59) 14.6 (5) 13.8 (4)
No 91.5% (54/59) 11.4 (3) 11 (3.2)
Nebulized epinephrine 0.281 (P)
Yes 74.6% (44/59) 12 (3.2) 11.8 (2.9)
No 91.5% (54/59) 11.4 (3) 11 (3.2)
Antibiotics 0.132 (P)
Yes 50.8% (30/59) 12.7 (3) 11.9 (3.2)
No 49.2% (29/59) 10.7 (3.3) 10.7 (3.2)
Heliox 0.002 (P)
Yes 34.5% (20/58) 14.2 (3.3) 13.2 (2.7)
No 65.5% (38/58) 10.4 (2.5) 10.3 (3.1)
Suspected bacterian (super)infection 0.173 (P)
Yes 39.7% (23/58) 12.5 (3) 12 (3.6)
No 60.3% (35/58) 11.2 (3.4) 10.8 (3.1)
RSV detected4 0.251 (O1)
Yes 81.0% (47/58) 12 (3.3) 11.6 (3.2)
No 19.0% (11/58) 10.6 (3.5) 10.1 (3.8)
PICU admission < 0.001
Yes 13.8% (8/58) 17.4 (2.1) 15.9 (2.5)
No 86.2% (50/58) 10.8 (2.5) 10.6 (2.7)
Wood-Downes Score <0.001
< = 3 26.5% (13/49) 10.0 (2.2) 8.5 (2.8)
4–6 57.1% (28/49) 11.4 (2.6) 11.7 (2)
> = 7 16.3% (8/49) 16.8 (3.1) 15.9 (2.5)
Hospital Length of Stay5 7.6 (2.8) 0.35 0.33 0.027 (P)
1 Descriptive analysis: Data are expressed either as % (n/total of patients for which this condition was recorded in medical history) or as mean (SD).
2 Mean (standard deviation) of ReSVinet scale according to each rater and the different variables. Correlation was assessed by Wilcoxon’s test for
dichotomic variables, Kruskal-Wallis for discrete variables with more than two categories and Spearman’s correlation for continuous variables.
3 The p-value seen on the table is that of the least significant value from any of the observers (between brackets the observer presenting that value is
indicated).
4 The method used for detecting RSV (Respiratory Syncytial Virus) in respiratory secretions of our patients was direct immunofluorescence.
5 Spearman’s correlation coefficient was used for the statistical analysis. Mean length of stay expressed as days (SD).
doi:10.1371/journal.pone.0157665.t004
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of the cases, but could not be definitively linked to a more aggressive course of infection (i.e,
achieving higher scores in the scale). No differences were found in the score when comparing
younger patients to older ones, regardless of the person carrying out the assessment, but this
observation lacked statistical significance (P-value = 0.790 for G1 and P-value = 0.880 for G2).
Interventions such as nebulized epinephrine and inhaled or oral corticosteroids could not be
related with significant changes in the final score. Children on antibiotics did receive a higher
score value in the paediatrician-assessed cohort G1 (mean difference range: 2.2–2.4), and this
difference could be attributable to endovenous prescriptions (P-value< 0.001), but not to oral
ones (P-value = 0.980). Similarly, scores of children with suspected bacterial super-infection
presented also a greater score than those discharged without that suspicion (mean difference
range: 1.7–1.9, P-value = 0.001).
Severity was defined by admission to PICU. Those infants who required intensive care pre-
sented a significantly higher score than those admitted to wards (15.7 ± 2.6 vs. 10.2 ± 2.5 when
evaluated by O1, 15.4 ± 2.7 vs. 9.2 ± 2.4 for O2, 14 ± 2.6 vs. 9.4 ± 2.4 for O3 in the professional
cohort, P-value< 0.001 for all of these values). These results could be replicated in the parental
subgroup (15.9 ± 2.5 for vs. 10.6 ± 2.7 for those children assessed by their parents, P-
value< 0.001). Cut-points analysis shows that a “severe episode” can be defined when a child
scores 14 points in our scale. If severity of the episode was defined instead by obtaining a value
in the “severe” range of theWDS (face value), we also found that values 14 in the ReSVinet
scale were associated with values of 7 in theWDS; this association was found to bear statistical
significance when comparing these patients to those who presented a “moderate” severity
(defined by obtaining a 4, 5 or 6 in theWDS): in the first cohort results were 15.1 ± 3.1 vs.
11.1 ± 2.7 for O1, 14.7 ± 3.0 vs. 10.2 ± 2.7 for O2, 13.7 ± 2.9 vs. 10.2 ± 2.5 for O3; and parental val-
ues (G2) were 15.9 ± 2.5 vs. 11.7 ± 2.0 (P-value< 0.001 for all of these observations). Mean values
and standard deviation fromO1 for patients in parental cohort (G2) were 16.8 ± 3.1 vs.
11.4 ± 2.6. In both cohorts, higher results meant a higherWDS (P-value< 0.001 for G1 and G2).
Length of stay had a significant positive correlation with the total value of the scale (r: 0.48–
0.60 for G1, P-value< 0.001, and r: 0.33–0.35 for G2, P-value = 0.027).
Parents found the scale easy to understand, and they could complete it in less than two min-
utes. For investigators, all the information required in the scale was accessible through electronic
clinical records. Investigators needed about five minutes to review the clinical record of a patient.
Discussion
The ReSVinet scale fulfills most of the requirements of an acceptable scoring system (Table 5)
[5, 12,13,14] with the added value of avoiding the need for in-person evaluation and allowing
an adapted version that is useful for non-professional assessment of the patient status.
Fig 1. Comparison of results obtained (A) by the three observers, and (B) by the parents and one of the
observers. In graph A: O1- Results obtained by observer 1. O2- Results obtained by observer 2. O3- Results
obtained by observer 3. In graph B: O1- Results obtained by observer 1. P—Results obtained by the parents.
doi:10.1371/journal.pone.0157665.g001
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Our scale showed a good internal consistence and an acceptable inter-observer reliability
even when tested by non-medical personnel. Most of the literature concerning scale validation
deals with information obtained by only two investigators [5, 15], so having an acceptable
weighted kappa index for more than two investigators is a relevant asset [5]. Intra-observer
reliability or test-retest procedures can be assumed to be good if the inter-observer reliability is
acceptable [12]. Hypotheses chosen as outcomes for testing face validity were correct for the
WDS and discriminating the severity of the illness, and length of hospital stay also correlated
positively with higher values of the scale in both groups.
So far, none of the many scores used for assessing the degree of dyspnea in patients with
acute respiratory infections has been sufficiently validated to allow clinically meaningful use in
children [5]. Our scale performed positively in 9 of the 15 items required. To the best of our
knowledge, there are only a few scales whose validation criteria have been tested so thoroughly,
and even fewer meeting more quality criteria than the ReSVinet scale [5]. The exclusion of dif-
ferent parameters by an expert panel is debatable, as there is ample evidence that some of them
(such as peripheral oxygen saturation) are associated with longer admission and invasive mea-
sures [7]. The main points of disagreement concerned the inclusion of oxygen saturation and
heart frequency, as both of them are frequently used in other scoring systems [16]. In the end,
both were intentionally left out of the scale. Oxygen saturation is not always available in an
Table 5. Check-list of the characteristics of the ReSVinet scale according to the desired properties of a clinical scale validated for use in infants
with acute respiratory infections*. The “considerations” column explains whether the ReSVinet scale meets the requirement. N.A. = not assessed.
Property Assessment Considerations for the ReSVinet scale
Validity
Face validity Yes The ReSVinet scale complies with 4 out of 5 points. Respiratory or heart rate (Q4), work of breathing (Q3),
wheezing/auscultatory findings (Q3), mental status (Q6).
Content validity Yes Development of the score, target population and item selection are described in this paper.
Construct validity Partially No current gold standard. Used WDS, PICU admission and length of stay as criteria of severity for correlating
hypothesis. The ReSVinet scale complied with all of them.
Criterion-concurrent
validity
Partially No current gold standard. Could be compared to SaO2 or pulmonary function (not done in this study), or
cyanosis (deemed not feasible for a parent-oriented scale, as it could be difficult to evaluate).
Reliability
Measurement error N.A. Absolute measurement error, usually expressed as smallest detectable change (SDC) i.e. the smallest
within-person change in score that can be interpreted as real change above measurement error. Not
evaluated.
Inter-observer reliability Yes Weighed kappa > 0.70 in a sample including more than 50 patients.
Intra-observer reliability N.A. Neither the investigators nor the parents re-evaluated their children.
Internal consistency Yes Cronbach’s alpha > 0.70.
Responsiveness Ongoing Currently being tested. Not evaluated in this paper.
Utility
Suitability for use in
children
Yes No invasive techniques are required in this scale.
Age span Partially Although the ReSVinet Scale was designed to cover the entire pediatric lifespan, in this study it was tested
only in children younger than 2 years of age.
Ease of scoring Yes < 4 categories per item.
Auscultation skills Yes No auscultation skills needed.
Floor or ceiling effect Yes <15% of patients with the lowest or the highest possible score in at least 50 patients.
Interpretability Yes Mean scores and standard deviation were calculated for clinical relevant subgroups. Results should be
reassessed for patients older than 2 years, seen in outpatient settings or with chronic debilitating pathologies.
* List of items adapted from Bekhof J, Reimink R, Brand PL. Systematic review: insufficient validation of clinical scores for the assessment of acute
dyspnoea in wheezing children. Paediatric Respiratory Reviews. 2014;15(1):98–112.
doi:10.1371/journal.pone.0157665.t005
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outpatient setting. When used, recent studies show that its value in the decision-making pro-
cess when facing a child with bronchiolitis may have been overestimated, leading to a higher
rate of admissions [17]; physicians tend to abuse this “objective”measurement even when
many do not understand its basis, placing great value on a difference of 2%, which is the accu-
racy most manufacturers report for their machines [18]. Parents also rely greatly on peripheral
oxygen saturation when their child is admitted [19], and they could be prone to underestimate
the true severity of the disease if this particular parameter is good enough for them. This vari-
able was definitively discarded as its inclusion in the ReSVinet scale would hamper its usability
by non-medical personnel–given the need of a device and training in probe placement and
data interpretation–as well as its applicability in an outpatient setting. The need of oxygen sup-
plementation (the intervention normally undertaken in patients with low oxygen saturation) is
in any case covered in Q2. The “heart rate” parameter is featured in the most widely used scor-
ing system, WDS [9], but its cut-off (120 beats per minute) is poorly discriminative in children
under two years as it can be secondary to fever, irritability, pain, excitement, bronchodilators,
or even a physiological heart rate in youngest ones. Another scores have defined higher cut-off
values for this parameter. In the score designed by Marlais et al., the heart rate was the best of
the five items chosen as predictors for admission[16], but since this was a retrospective study,
this parameter was not compared with the heart rate of children being discharged directly from
the emergency department; furthermore a higher heart rate may in any case be related to a
more aggressive course of bronchodilators prior to admission. Wheezing is another item fre-
quently included in respiratory assessment scales [4,6,9], but it can be difficult to explain, medi-
cal material (stethoscope) could be required for its assessment, and case definition of
bronchiolitis in several countries does not require wheezing for the diagnosis [20, 21]. We
chose instead to address the “respiratory noise” in Q3, as this concept is more understandable
by non-medical personnel. The ReSVinet scale covers feeding difficulties (Q1), which have
been related in several studies with greater risk of admission and invasive medical interventions
[22,23,24] but are neglected by many of the scores already in use in clinical trials [4,5,7]. What
is more, some of the most widely used scales deal only with the respiratory impact of the dis-
ease, like the Respiratory Disease Assessment Instrument (RDAI) or the Respiratory Assess-
ment Change Score (RACS), both of which are widely used but have shown poor to moderate
construct validity [4]; they even neglect findings such as hypoventilation and episodes of
apnea. This particular concern is also found in scales more directed to asthmatic patients, like
the Pulmonary Score [25]. Last, general condition is another parameter of our clinical scoring
system which is usually not included in most of the existing scales, despite the fact that most
clinicians seek and value the parental opinion on how severely affected they think their off-
spring are.
Our results suggest that this score has a reliable performance when calculating the respira-
tory difficulty from clinical records, making in-person evaluation not necessary. This feature
could be of extraordinary value for clinical trials, where frequent in-person assessment and
close follow-up is usually required when a participant presents with an adverse event such as
bronchiolitis. Moreover, this could also be an asset in everyday clinical practice, allowing the
primary care physician to obtain an impression of the condition of the infant at the moment of
discharge from the emergency department, or their previous condition in a center that has just
referred the patient for interment in another institution. In cases where medical records are not
available or are not sufficient to allow the correct use of this score by the physician, parents
could evaluate their children with results that can be compared to those of a physician. To the
best of our knowledge, there is no other scale which shares these two advantages with the
ReSVinet scale.
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Limitations of our study include the lack of responsiveness in our currently gathered data,
that the score was tested only on hospitalized patients younger than two years of age, and the
inexistence of a gold standard for the evaluation of children with acute lower respiratory infec-
tion. Most of our patients suffered from acute bronchiolitis which, although the most frequent
ARI during infancy, may not represent the whole spectrum of respiratory infections in the first
2 years. A memory bias was a possible confounding factor for the parents who filled in the
score (as they completed it at the moment of discharge with the sole help of what they remem-
bered), whereas quality and accuracy of clinical records could influence the results of the
observers. Another reservation about the results presented in this study is that the professionals
reviewing the clinical records were experienced pediatricians. Further testing may be required
to ensure investigators with a different profile conduct the evaluation of clinical records with
comparable precision. It could also be argued that clinicians may also bias the results as medi-
cal interventions influence the final outcome of the scoring system. However, the opposite
could be argued too, as many decisions of pediatricians could be affected by the final score of
any scale they use. Despite this potential risk of doctors’ decisions impacting the outcome of
the scale, it was not possible to demonstrate that use of drugs, such as nebulized epinephrine or
oral medication (corticosteroids or antibiotics), was associated with a significant increase in the
final score in any of the two cohorts. In fact, severity range in the ReSVinet Scale correlated
well with the definition of severity in the WDS, where medical interventions are not consid-
ered. It must be noted that there was a significant overlap between values that would corre-
spond to “mild” and “moderate” episodes in the WDS, a finding that could be explained
because the scale has only been applied to hospitalized children.
The final score value for patients in our setting did not show any difference dependent on
the pathogen infecting them. In studies concerning other scoring systems, patients suffering
from RSV had a higher total score [26]. Our scale failed to demonstrate any statistically signifi-
cant impact of prematurity in the score, even though those children are at risk of worse epi-
sodes of bronchiolitis and many of them should receive prophylaxis against RSV [27].
Children of younger age in our study had a similar mean score to that obtained in older
patients, although this finding lacked statistical significance. This can be explained by an insuf-
ficient number of subjects in both cohorts or the fact that we excluded children with chronic
pulmonary conditions (which is a frequent problem in prematurely born babies); however, this
outcome has already been described in medical literature [26], probably explained by the
widely accepted measure of preemptively interning prematurely born children and younger
infants. Aspects such as distance to a health provider, parental stress, or need for endovenous
rehydration influence the decision of discharging a patient from the Emergency Department,
and they are usually not gathered in respiratory scales nor clinical records. At the same time, a
previous episode of wheezing was linked to a more severe disease in the cohort assessed by pro-
fessionals but not in the parental cohort, which may be attributed to the significant lower mean
age of the latter group. Neither the impact of maternal smoking during pregnancy nor breast-
feeding were addressed in this study, although there is ample evidence of their influence in the
severity of the disease [2].
The next steps for completing the validation of this score should include the application of
this scale in outpatient settings, expansion of the age span of the scale to those children older
than two years, and the inclusion of other pathologies which primarily manifest with respira-
tory difficulty in older children (asthma, atypical causes of pneumonia. . .) or in patients with
underlying conditions. More importantly, the responsiveness of the ReSVinet scale should also
be assessed. If the ReSVinet scale’s performance regarding responsiveness is acceptable, this
scale will prove to be an important tool for the evaluation of infants suffering from respiratory
infections.
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Conclusions
Our results indicate that the ReSVinet severity score has adequate criterion validity, adequate
construct validity, adequate inter-rater reliability, and appropriate usability for infants under
two years of age hospitalized for acute respiratory infections, even when used by non medical-
personnel or when evaluating patients using clinical records and therefore avoiding the need
for in-person evaluation of the subject by a physician. Although this scale still does not meet all
the criteria for a perfectly validated scale, it complies with far more of them than the vast
majority of the alternatives currently available and used in the clinical practice.
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